Drug Trial Radar · NCT07104877
A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors
Last checked: Nov 20, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
25
Actual
Start
Apr 18, 2024
Primary completion
Nov 1, 2024
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Fujian Cancer HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, non-randomized trial design, including a dose escalation phase and a dose expansion phase, to evaluate the safety, tolerability and preliminary anti-tumor activity of SYS6010 in combination with SYH2051 in patients with advanced gastrointestinal tumors.
Conditions
- Colorectal Cancer
- Gastric Cancer (GC)
- Gastrointestinal Tumors
Interventions
SYS6010Drug
Administered via intravenous infusion at the dose of 3.2-4.8 mg/kg
SYH2051Drug
Administered via oral at the dose of 40-80 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event (AE)Time frame: Up to 90 days following the last dose
- Dose-limiting toxicities (DLTs)Time frame: Up to 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.